{"id":"https://openalex.org/W4361840238","doi":"https://doi.org/10.1158/0008-5472.22390946.v1","title":"Supplementary Materials and Methods from Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis","display_name":"Supplementary Materials and Methods from Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis","publication_year":2023,"publication_date":"2023-03-30","ids":{"openalex":"https://openalex.org/W4361840238","doi":"https://doi.org/10.1158/0008-5472.22390946.v1"},"language":"en","primary_location":{"id":"doi:10.1158/0008-5472.22390946.v1","doi":"https://doi.org/10.1158/0008-5472.22390946.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/0008-5472.22390946.v1","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Materials_and_Methods_from_Human_CD59_Inhibitor_Sensitizes_Rituximab-Resistant_Lymphoma_Cells_to_Complement-Mediated_Cytolysis/22390946/1/files/39836480.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Materials_and_Methods_from_Human_CD59_Inhibitor_Sensitizes_Rituximab-Resistant_Lymphoma_Cells_to_Complement-Mediated_Cytolysis/22390946/1/files/39836480.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5101738196","display_name":"Weiguo Hu","orcid":"https://orcid.org/0000-0003-2156-6233","observed_orcids":["https://orcid.org/0000-0003-2156-6233"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Weiguo Hu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110741632","display_name":"Xiaowen Ge","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xiaowen Ge","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112657990","display_name":"Tao You","orcid":"https://orcid.org/0000-0003-2381-7382","observed_orcids":["https://orcid.org/0000-0003-2381-7382"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tao You","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100385908","display_name":"Ting Xu","orcid":"https://orcid.org/0000-0003-2578-6532","observed_orcids":["https://orcid.org/0000-0003-2578-6532"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ting Xu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100709961","display_name":"Jinyan Zhang","orcid":"https://orcid.org/0000-0002-9874-2744","observed_orcids":["https://orcid.org/0000-0002-9874-2744","https://orcid.org/0009-0003-5168-8327","https://orcid.org/0000-0002-9205-7607"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jinyan Zhang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102051693","display_name":"Gongxiong Wu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gongxiong Wu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101460867","display_name":"Zhihai Peng","orcid":"https://orcid.org/0000-0002-0928-931X","observed_orcids":["https://orcid.org/0000-0002-0928-931X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Zhihai Peng","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113917509","display_name":"Michael Chorev","orcid":"https://orcid.org/0000-0003-3533-2913","observed_orcids":["https://orcid.org/0000-0003-3533-2913"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michael Chorev","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020661635","display_name":"Bertal Huseyin Aktas","orcid":"https://orcid.org/0000-0001-7829-4553","observed_orcids":["https://orcid.org/0000-0001-7829-4553"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bertal H. Aktas","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086918952","display_name":"Jos\u00e9 A. Halperin","orcid":"https://orcid.org/0000-0003-4749-5285","observed_orcids":["https://orcid.org/0000-0003-4749-5285"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jose A. Halperin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016570475","display_name":"Jennifer R. Brown","orcid":"https://orcid.org/0000-0003-2040-4961","observed_orcids":["https://orcid.org/0000-0003-2040-4961"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jennifer R. Brown","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5002075826","display_name":"Xuebin Qin","orcid":"https://orcid.org/0000-0001-9875-983X","observed_orcids":["https://orcid.org/0000-0001-9875-983X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xuebin Qin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10993","display_name":"Complement system in diseases","score":0.9843999743461609,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10993","display_name":"Complement system in diseases","score":0.9843999743461609,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.011099999770522118,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11020","display_name":"Immune Cell Function and Interaction","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/rituximab-resistance","display_name":"rituximab resistance","score":0.9860000014305115},{"id":"https://openalex.org/keywords/lymphoma","display_name":"lymphoma","score":0.7379999756813049},{"id":"https://openalex.org/keywords/complement-mediated-cell-lysis","display_name":"complement-mediated lysis","score":0.9340000152587891},{"id":"https://openalex.org/keywords/complement-system","display_name":"complement system","score":0.5540000200271606},{"id":"https://openalex.org/keywords/complement-regulatory-proteins","display_name":"complement regulatory proteins","score":0.5460000038146973},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.6079999804496765}],"concepts":[{"id":"https://openalex.org/C73588182","wikidata":"https://www.wikidata.org/wiki/Q2663023","display_name":"Cytolysis","level":4,"score":0.7883921265602112},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.6127225160598755},{"id":"https://openalex.org/C112313634","wikidata":"https://www.wikidata.org/wiki/Q7886648","display_name":"Complement (music)","level":5,"score":0.5606231689453125},{"id":"https://openalex.org/C184404459","wikidata":"https://www.wikidata.org/wiki/Q5009828","display_name":"CD59","level":4,"score":0.5597246289253235},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.49613985419273376},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.478375107049942},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.32112330198287964},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3161281943321228},{"id":"https://openalex.org/C111684460","wikidata":"https://www.wikidata.org/wiki/Q334848","display_name":"Complement system","level":3,"score":0.3088439702987671},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.2815014719963074},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.20996806025505066},{"id":"https://openalex.org/C109316439","wikidata":"https://www.wikidata.org/wiki/Q246181","display_name":"Cytotoxicity","level":3,"score":0.14395684003829956},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.07332932949066162},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.06283140182495117},{"id":"https://openalex.org/C127716648","wikidata":"https://www.wikidata.org/wiki/Q104053","display_name":"Phenotype","level":3,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C188082640","wikidata":"https://www.wikidata.org/wiki/Q1780899","display_name":"Complementation","level":4,"score":0.0}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.1158/0008-5472.22390946.v1","doi":"https://doi.org/10.1158/0008-5472.22390946.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/0008-5472.22390946.v1","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Materials_and_Methods_from_Human_CD59_Inhibitor_Sensitizes_Rituximab-Resistant_Lymphoma_Cells_to_Complement-Mediated_Cytolysis/22390946/1/files/39836480.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"doi:10.1158/0008-5472.22390946","doi":"https://doi.org/10.1158/0008-5472.22390946","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/0008-5472.22390946","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/22390946","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Materials_and_Methods_from_Human_CD59_Inhibitor_Sensitizes_Rituximab-Resistant_Lymphoma_Cells_to_Complement-Mediated_Cytolysis/22390946","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/0008-5472.22390946.v1","doi":"https://doi.org/10.1158/0008-5472.22390946.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/0008-5472.22390946.v1","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Materials_and_Methods_from_Human_CD59_Inhibitor_Sensitizes_Rituximab-Resistant_Lymphoma_Cells_to_Complement-Mediated_Cytolysis/22390946/1/files/39836480.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"score":0.9391000270843506,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4361840238.pdf","grobid_xml":"https://content.openalex.org/works/W4361840238.grobid-xml"},"referenced_works_count":3,"referenced_works":["https://openalex.org/W1760063727","https://openalex.org/W1993136765","https://openalex.org/W2095291612"],"related_works":["https://openalex.org/W2130867811","https://openalex.org/W4392725819","https://openalex.org/W2062943168","https://openalex.org/W2153255423","https://openalex.org/W4361944094","https://openalex.org/W2032454178","https://openalex.org/W33733012","https://openalex.org/W2065316818","https://openalex.org/W2039226259","https://openalex.org/W2069524809"],"abstract_inverted_index":{"Supplementary":[0],"Materials":[1],"and":[2],"Methods":[3],"from":[4],"Human":[5],"CD59":[6],"Inhibitor":[7],"Sensitizes":[8],"Rituximab-Resistant":[9],"Lymphoma":[10],"Cells":[11],"to":[12],"Complement-Mediated":[13],"Cytolysis":[14]},"counts_by_year":[],"updated_date":"2026-11-09T13:22:03.289127","created_date":"2023-04-05T00:00:00"}